Skip to main content

Table 4 Subgroup analysis of PFS and OS in non-small cell lung cancer patients with multiple therapies

From: Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

Study name Year Treatment Cancer type Media PFS (months) Z-Value P-Value Media PFS (months) Z-Value P-Value
NCT02358473 2018 mogamulizumab +docetaxel NSCLC 2.243 (95% CI:1.235–3.250) 4.364 0.000 7.335 (95% CI:5.657–9.013) 8.570 0.000
Doi, T 2019 mogamulizumab +nivolumab NSCLC 2.600 (95% CI:1.669–3.531) 5.473 0.000 6.075 (95% CI:4.838–7.312) 9.629 0.000
Overall     2.435 (95% CI:1.752–3.119) 6.982 0.000 6.519 (95% CI:5.523–7.514) 12.836 0.000
  1. Abbreviation: NSCLC non-small cell lung cancer